After US FDA Advisors Unanimously Back First OTC Naloxone Proposal, Meeting On Second Not Needed
Executive Summary
“Meeting is no longer needed,” agency states in announcement. The same committees’ unanimous recommendation during a meeting in February on Emergent’s sNDA for OTC sales of 4-mg naloxone nasal spray made a repeat for HRT’s NDA for 3-mg spray unnecessary.